SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully ...
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication by Diabetes Technology & Therapeutics of a meta-analysis of three ...
The US Food and Drug Administration (FDA) has cleared Tandem Diabetes Care’s Control-IQ+ technology, an automated insulin delivery algorithm, for use in individuals aged 18 and above with type 2 ...
Automated Insulin Dosing Software First to Receive New Classification by FDA All in-warranty t:slim X2 pump users in the United States will have the option to add the new feature free of charge via ...
– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results